Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

ACOG

Alpha Cognition (ACOG)

Alpha Cognition Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACOG
DateHeureSourceTitreSymboleSociété
16/04/202521h18Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACOGAlpha Cognition Inc
10/04/202522h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACOGAlpha Cognition Inc
10/04/202514h30Business WireAlpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John HavensNASDAQ:ACOGAlpha Cognition Inc
31/03/202522h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACOGAlpha Cognition Inc
31/03/202514h30Business Wire Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewNASDAQ:ACOGAlpha Cognition Inc
19/03/202521h30Business WireAlpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewNASDAQ:ACOGAlpha Cognition Inc
18/03/202513h30Business WireAlpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s DiseaseNASDAQ:ACOGAlpha Cognition Inc
12/02/202514h30Business WireAlpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s diseaseNASDAQ:ACOGAlpha Cognition Inc
22/01/202513h00GlobeNewswire Inc.OTC Markets Group Announces Quarterly Index Performance and RebalancingNASDAQ:ACOGAlpha Cognition Inc
14/01/202514h30Business WireAlpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYLNASDAQ:ACOGAlpha Cognition Inc
10/01/202512h20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ACOGAlpha Cognition Inc
10/01/202512h12Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ACOGAlpha Cognition Inc
08/01/202514h30Business WireAlpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in ChinaNASDAQ:ACOGAlpha Cognition Inc
06/01/202514h30Business WireAlpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update CallNASDAQ:ACOGAlpha Cognition Inc
16/12/202420h56Business WireAlpha Cognition Announces Partial Exercise of Over-allotment OptionNASDAQ:ACOGAlpha Cognition Inc
13/12/202400h41Business WireAlpha Cognition Announces Voluntary Delisting from CSENASDAQ:ACOGAlpha Cognition Inc
11/12/202414h30Business WireAlpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain InjuryNASDAQ:ACOGAlpha Cognition Inc
15/11/202423h00Business WireAlpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate UpdateNASDAQ:ACOGAlpha Cognition Inc
12/11/202415h22Business WireAlpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq ListingNASDAQ:ACOGAlpha Cognition Inc
 Showing the most relevant articles for your search:NASDAQ:ACOG

Dernières Valeurs Consultées

Delayed Upgrade Clock